Delta Sleep-Inducing Peptide (DSIP): Research, Evidence, and What to Know

Key Takeaways

• Compound covered: DSIP (delta sleep-inducing peptide), a nonapeptide originally isolated from rabbit brain
• Goal area: Sleep regulation, circadian rhythm, stress modulation, pain management (research contexts)
• Evidence range: Small human clinical studies (insomnia, withdrawal, pain) from the 1980s–1990s; preclinical mechanistic data; no modern adequately powered controlled trials
• Regulatory range: Research-only; not FDA-approved for any indication; not legally available by prescription in the US
• Key biomarkers for sleep: Cortisol (HPA axis / circadian), TSH (thyroid), IGF-1 (GH pulse during sleep), hs-CRP (inflammatory burden), CBC
• As of April 2026: DSIP has no FDA-approved indication and is not available through Superpower or any licensed prescriber in the US.
• Bottom line: DSIP has mechanistically interesting preclinical and limited human data, but no adequately powered modern trial has validated its clinical efficacy for sleep or any other indication.

Understanding Sleep: The Biology

Human sleep is not a passive state — it is an actively regulated biological process governed by two interacting systems: the homeostatic sleep drive (Process S), which accumulates adenosine and other sleep-promoting signals during wakefulness, and the circadian clock (Process C), synchronized by light and anchored in the suprachiasmatic nucleus (SCN) of the hypothalamus.

Sleep architecture consists of alternating cycles of non-REM (NREM) and REM sleep. NREM sleep includes stages N1 through N3, with N3 (slow-wave or deep sleep) being widely considered the most biologically restorative phase — characterized by high-amplitude delta-wave EEG activity, growth hormone pulse release, and metabolic restoration. REM sleep is associated with memory consolidation and emotional processing.

Multiple peptide systems regulate sleep architecture. Neuropeptides including growth hormone-releasing hormone (GHRH), corticotropin-releasing hormone (CRH), somatostatin, and orexin modulate transitions between sleep stages and the timing of hormonal pulses that occur during sleep. A comprehensive 1997 review by Steiger and Holsboer in Sleep situated DSIP within sleep neuropeptides and established that sleep regulation is fundamentally a neuropeptide-dependent process. A 2004 review by Prospéro-García and Méndez-Díaz in Drug News & Perspectives surveyed peptide systems and sleep-wake circuitry across multiple neurotransmitter axes.

Peptides are relevant to sleep because sleep architecture is regulated by peptide signaling at every level — from the hypothalamic-pituitary axis to brainstem monoamine systems. DSIP was identified as a specific sleep-promoting signal; understanding why its clinical development stalled requires understanding the complexity of that regulatory environment.

Peptides Studied for Sleep: Where DSIP Fits

DSIP occupies a specific and unusual position: it was one of the first peptides specifically isolated for sleep-inducing activity, but its clinical translation has been limited by biological complexity, bioavailability challenges, and insufficient modern research. The following comparison positions DSIP relative to other neuropeptides with published sleep-relevant evidence.

• Compound: DSIP (delta sleep-inducing peptide)
  Mechanism for sleep: Proposed modulation of delta-wave activity; MAO-A regulation affecting serotonin; opioid peptide interactions; blood-brain barrier penetration documented
  Evidence: Small human studies (N typically under 30) from 1981–1992 showing sleep improvement; preclinical mechanistic data; no modern RCT
  FDA status: Research-only; not approved for any indication
  SP availability: Not available through Superpower or any licensed prescriber
  Route: Intravenous in research studies; research compounds sold online are unregulated
• Compound: GHRH (growth hormone-releasing hormone analogs)
  Mechanism for sleep: GHRH receptors in cortex locally regulate EEG delta waves; GH pulse during slow-wave sleep is GHRH-dependent
  Evidence: Controlled human studies of GHRH effects on sleep EEG; more mechanistically established than DSIP
  FDA status: Sermorelin (a GHRH analog) is a USP monograph compound eligible for 503A compounding through the USP/NF pathway (21 U.S.C. § 353a(b)(1)(A)(i)); tesamorelin is FDA-approved for HIV lipodystrophy only
  SP availability: Sermorelin may be available through Superpower's licensed provider network subject to clinical evaluation, eligibility, current 503A Category status (subject to PCAC review and periodic FDA updates), and applicable state-level pharmacy regulations; compounded, not FDA-approved
  Route: Subcutaneous injection
• Compound: Epitalon (AEDG; synthetic pineal tetrapeptide)
  Mechanism for sleep: Melatonin rhythm normalization through pineal gland regulation
  Evidence: Small human and primate studies showing circadian melatonin normalization in elderly subjects
  FDA status: Not FDA-approved; removed from the FDA Category 2 interim 503A bulks list on April 22, 2026, pending PCAC review; not currently eligible for 503A compounding
  SP availability: Not available through Superpower; not eligible for 503A compounding under current FDA policy
  Route: Subcutaneous injection

Compounds listed as "research-only" have not completed the clinical trial process required for FDA approval. They are not legal to prescribe or sell for human use in the US. Their inclusion here is for educational context only.

DSIP: In Depth

DSIP's research history spans more than five decades. What follows covers its discovery, mechanism, human evidence, and the reasons it remains what Kovalzon and Strekalova aptly called "a still unresolved riddle."

Discovery and structure

DSIP was characterized in the 1970s by Marcel Monnier, Schoenenberger, and colleagues at the University of Basel after cross-circulation experiments showed that dialysate taken from the thalamic venous blood of sleeping rabbits could induce slow-wave sleep in recipient rabbits. The peptide was characterized as a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. A 1984 foundational review by Graf and Kastin in Neuroscience and Biobehavioral Reviews summarized DSIP isolation and sleep-inducing properties, including the original rabbit EEG evidence.

DSIP is found in the hypothalamus, limbic system, pituitary, and peripheral tissues. It circulates in blood in both free and bound forms. A 1986 update review by Graf and Kastin in Peptides surveyed DSIP's biological functions beyond sleep, including endocrine modulation of LH, cortisol, GH, and ACTH — establishing early that DSIP was not a simple, single-purpose sleep signal. [Preclinical / Early human data]

Mechanism: how DSIP may affect sleep and the nervous system

DSIP's CNS access has been confirmed: a 1988 study by Zlokovic and colleagues in Peptides demonstrated that DSIP crosses the blood-CSF barrier, a finding that distinguishes it from larger peptides that cannot penetrate into the brain. The characterization of DSIP's properties by Schoenenberger, published in European Neurology in 1984, documented DSIP's multivariate functions and bioavailability challenges for clinical translation.

For serotonin and monoamine activity, a 1995 study by Khvatova and colleagues in FEBS Letters DSIP modulates MAO-A activity under hypoxia — MAO-A being the enzyme primarily responsible for serotonin degradation. For hypothalamic-pituitary interactions, a 1987 study by Iyer and McCann in Neuroendocrinology DSIP inhibits somatostatin via dopaminergic mechanism, providing a pathway through which DSIP might influence GH secretion during sleep.

For antioxidant and neuroprotective effects, a 2003 study by Khvatova and colleagues in Peptides examined DSIP and mitochondrial respiration under hypoxia. For opioid interactions, a 1989 study by Nakamura and colleagues in Brain Research DSIP stimulates Met-enkephalin release in brainstem, linking DSIP to endogenous opioid pathways involved in both sleep and pain modulation. None of these mechanisms have been fully validated in humans at therapeutic doses.

What the human sleep studies show

The human evidence for DSIP spans a small set of clinical studies conducted primarily in the 1980s. The most directly relevant is a 1987 study by Monti and colleagues in the International Journal of Clinical Pharmacology Research showing short-term sleep improvement in chronic insomniacs — the most directly controlled human clinical citation for the insomnia application. A 1981 study by Schneider-Helmert and Schoenenberger in Experientia DSIP improved disturbed human sleep.

A 1984 clinical trial by Kaeser in European Neurology documented EEG findings in sleep-disorder patients. A 1981 study by Schneider-Helmert and colleagues in the International Journal of Clinical Pharmacology, Therapy, and Toxicology DSIP effects in healthy humans, insomniacs, noting variation in the onset and duration of effects. A 1992 double-blind study by Bes and colleagues in Neuropsychobiology evaluated DSIP in chronic insomnia patients, providing additional human sleep evidence.

For circadian applications, a 1987 report by Schneider-Helmert and colleagues in Deutsche Medizinische Wochenschrift described DSIP for phase-shifted circadian insomnia, suggesting relevance to jet-lag or shift-work contexts. [Phase II or earlier; small N]

The consistent limitation across all of these studies: small sample sizes, no placebo-controlled designs in most cases, and publication in an era before modern polysomnography and sleep staging standards. No study in this group would meet current regulatory evidence thresholds for drug approval.

Withdrawal, pain, and other research directions

DSIP's clinical research has extended beyond sleep. A 1984 clinical pilot by Dick and colleagues in European Neurology evaluated DSIP in alcohol and opiate withdrawal, reporting symptom improvement in most participants. A 1984 pilot by Larbig and colleagues in European Neurology evaluated DSIP in chronic pain patients, reporting symptom improvement. A 1983 study by Dick and colleagues in Neuropsychobiology examined DSIP withdrawal and opiate receptor activity, reporting symptom reduction in a small pilot and noting potential opiate receptor agonistic activity.

Alcohol interactions were explored in a 1992 study by Yukhananov and colleagues in Pharmacology, Biochemistry, and Behavior examining ethanol, DSIP, and brain monoamines. These findings are preliminary clinical observations, not validated treatment data — but they illustrate the breadth of DSIP's proposed biological activity.

Why clinical development has not advanced

Several structural barriers have prevented DSIP from advancing through modern clinical development. The half-life problem is fundamental: a 1977 study by Marks and colleagues in Brain Research Bulletin rapid degradation of DSIP by brain extracts, which means any therapeutic application requires either frequent dosing, modified delivery systems, or structural analogues resistant to enzymatic breakdown. The 1984 characterization by Schoenenberger noted these bioavailability and half-life challenges explicitly.

The broader context is equally significant: the 2006 review by Kovalzon and Strekalova in the Journal of Neurochemistry surveyed DSIP's pleiotropic functions and research limitations, concluding that DSIP remains scientifically contested because its effects have not been consistently replicated across species or experimental conditions. Without a clear, single-mechanism target, building a regulatory development program is difficult.

Regulatory Status at a Glance

As of April 2026, DSIP carries the following regulatory status in the United States.

• DSIP: Research-only; not approved by the FDA for any indication. DSIP was removed from the FDA's Category 2 interim 503A bulks list on April 22, 2026, pending further review by the Pharmacy Compounding Advisory Committee (PCAC). Under current FDA policy, DSIP is not eligible for compounding under Section 503A and is not legally available by prescription in the US. It is not available through Superpower or any licensed prescriber.

Compounds listed as "research-only" are not legal to prescribe, compound, or sell for human use in the US. Their presence in this article is for educational context only.

Considerations When Evaluating DSIP

DSIP is not a compound that a licensed provider can prescribe, compound, or legally access for a patient in the United States as of April 2026. This significantly limits the clinical conversation. What the research record does support is the following framing.

Mechanism interest is real, clinical translation is not established: DSIP has biological mechanisms relevant to sleep regulation in preclinical and early human studies — it has been shown to cross the blood-CSF barrier, to modulate monoamine oxidase activity affecting serotonin metabolism, to interact with opioid peptide systems, and to inhibit somatostatin in ways that could influence growth hormone secretion during sleep. These are scientifically credible mechanisms. They are not the same as demonstrated clinical efficacy.

The human evidence base is narrow and dated: The most relevant human studies are small, predominantly not placebo-controlled, and were conducted before 1995. Direct comparison with modern sleep compound research is not appropriate. The evidence does not support clinical claims for DSIP.

Underlying sleep problems deserve biological evaluation: Persistent sleep disruption has identifiable biological causes — thyroid dysfunction, cortisol dysregulation, inflammatory burden, anemia, glucose dysregulation — that are measurable and addressable. Pursuing an unapproved research compound without a systematic evaluation of these factors is an inversion of the appropriate clinical sequence.

A licensed provider will evaluate the underlying biology driving sleep disruption before any FDA-approved or 503A-eligible compound is considered. Research-only compounds such as DSIP cannot be legally prescribed in the US regardless of clinical evaluation.

Safety Considerations

DSIP's human safety data is limited to the small clinical studies summarized above, most of which used intravenous administration in monitored research settings. No systematic adverse event data from controlled trials exists. No long-term human safety data exists at any dose. The compound has not been evaluated by the FDA for safety in any context.

Contraindications that apply broadly to research peptides used without medical supervision include:

• Pregnancy and breastfeeding: reproductive safety data does not exist for DSIP
• Concurrent use of monoamine oxidase inhibitors (MAOIs) or serotonergic medications: DSIP has proposed MAO-A modulatory activity; pharmacological interaction cannot be predicted
• Concurrent use of opioid medications: DSIP has proposed opioid system interactions; additive effects cannot be predicted
• Sourcing from unregulated online vendors: products sold as DSIP outside licensed pharmacy channels have not been evaluated for identity, purity, or potency

DSIP is a research-only compound. It cannot be legally prescribed in the US. This safety section is provided for educational completeness only.

What to Test Before Starting Peptides for Sleep

Baseline biomarker testing establishes the biological context for sleep disruption. Persistent sleep problems frequently have identifiable systemic causes that are measurable. Without this baseline, any subsequent intervention — peptide or otherwise — lacks a reference point for evaluating change.

• Cortisol: Elevated or dysregulated cortisol is a primary driver of sleep onset difficulty and early morning waking. Testing cortisol levels (ideally morning and evening to assess the diurnal pattern) characterizes HPA axis function and circadian alignment before any sleep-related intervention.
• TSH and free T4: Thyroid dysfunction is a common and underdiagnosed cause of sleep disruption. Both hypothyroidism and hyperthyroidism affect sleep architecture. Baseline TSH is a standard first-line thyroid screen.
• IGF-1: Growth hormone is secreted primarily during slow-wave sleep. A baseline IGF-1 level reflects integrated GH secretory activity and provides context for any peptide that interacts with GH-axis pathways (including GHRH analogs studied for sleep).
• hs-CRP: Systemic inflammation disrupts sleep architecture by activating the HPA axis and interfering with slow-wave sleep. Baseline hs-CRP quantifies inflammatory burden independently of any specific sleep complaint.
• CBC: Iron-deficiency anemia and restless legs syndrome have overlapping biology. Hemoglobin and RBC indices characterize oxygen-carrying capacity relevant to sleep quality. Ferritin (iron stores) should be assessed alongside CBC for anyone with sleep disruption and possible iron deficiency.
• Comprehensive metabolic panel: Glucose dysregulation affects sleep architecture. Liver and kidney function baselines are relevant safety context for any injectable compound a provider might consider.
• Vitamin B12: B12 deficiency is associated with altered sleep-wake cycle regulation through its role in melatonin synthesis pathways. Testing vitamin B12 alongside the broader panel identifies a common, correctable contributor to sleep disruption.

Cortisol, TSH, IGF-1, hs-CRP, and a comprehensive metabolic panel establish the HPA axis, thyroid, GH-axis, and inflammatory baselines most directly relevant to sleep biology. These markers also happen to be what a licensed provider would assess before considering any sleep-related compound — peptide or otherwise — providing the conversation context needed for any meaningful clinical evaluation.

Regulatory Status and Access: DSIP vs. Related Sleep Peptides

DSIP cannot be legally prescribed or compounded in the United States as of April 2026. A licensed provider cannot currently write a prescription for DSIP, and no licensed compounding pharmacy can compound it under Section 503A. DSIP was removed from FDA's Category 2 interim list on April 22, 2026 and is awaiting PCAC review. Products sold online as DSIP are not subject to FDA oversight, pharmaceutical-grade manufacturing, or quality verification.

Other peptides with sleep-related research — GHRH analogs like sermorelin, which has a USP monograph and is eligible for 503A compounding through 21 U.S.C. § 353a(b)(1)(A)(i) — may be accessed through licensed providers subject to current 503A Category status, clinical evaluation, and state-level pharmacy regulations. Any discussion of these compounds requires a clinical evaluation, baseline lab work, and a licensed provider who can assess eligibility, order compounded formulations from a licensed pharmacy, and monitor response. Epitalon is not currently eligible for 503A compounding pending PCAC review.

The appropriate first step for anyone with persistent sleep difficulty is a clinical evaluation with a licensed provider, including bloodwork to identify the systemic causes of sleep disruption before any compound is considered.

Understanding Your Baseline

DSIP illustrates a broader principle in sleep peptide research: mechanistic interest in a compound, even one with some early human data, does not substitute for an understanding of the individual's sleep biology. Cortisol dysregulation, thyroid function, inflammatory burden, B12 status, and GH-axis activity each represent identifiable and addressable contributors to poor sleep — contributors that bloodwork can characterize before any compound is discussed.

That evidence-first principle is central to Superpower's approach to preventive health. Whether the conversation with a provider leads to a compounded GHRH analog, a lifestyle modification, or a referral for sleep study, the starting point is objective biomarker data — not a compound search.

IMPORTANT SAFETY INFORMATION

DSIP (delta sleep-inducing peptide) is not approved by the FDA for any medical use. Research on this compound has been limited primarily to small laboratory and human studies conducted before 1995, with no adequately powered, placebo-controlled modern clinical trials. Its safety, efficacy, appropriate dosing, and long-term effects in humans have not been established. DSIP is not prescribed, compounded, or dispensed through Superpower. This page is provided for educational purposes only and does not constitute medical advice or an endorsement of use.

DSIP is not currently eligible for compounding under Section 503A. FDA removed DSIP from the Category 2 interim bulks list on April 22, 2026, and its status is pending PCAC review. It is not legally available by prescription in the United States. Products sold as DSIP through online vendors are unregulated and have not been evaluated by the FDA for safety, efficacy, or manufacturing quality.

Theoretical interactions requiring caution include: concurrent use of MAO inhibitors (DSIP has proposed MAO-A modulatory activity); concurrent use of opioid medications (DSIP has proposed opioid system interactions); pregnancy or breastfeeding (no reproductive safety data exists). These are not contraindication lists for a drug with an approved indication — DSIP has no approved indication.

Disclaimer: DSIP is a research-only compound not approved by the FDA for any medical use. It is not available through Superpower or any licensed prescriber. This article is for educational purposes only and does not constitute medical advice or an endorsement of use.